[1]都艳娜,李艳宾,王文静,等.血液灌流串联血液透析滤过对血液透析患者矿物质与骨异常的影响▲[J].内科,2020,15(06):654-657.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.06]
 DU Yanna,LI Yanbin,WANG Wenjing,et al.Effect of hemoperfusion combined with hemodiafiltration on mineral and bone disorder in hemodialysis patients[J].Internal Medicine of China,2020,15(06):654-657.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.06]
点击复制

血液灌流串联血液透析滤过对血液透析患者矿物质与骨异常的影响▲()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
654-657
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Effect of hemoperfusion combined with hemodiafiltration on mineral and bone disorder in hemodialysis patients
文章编号:
1673-7768(2020)06-0654-04
作者:
都艳娜李艳宾王文静崔宝伦
中国人民解放军联勤保障部队第九八八医院肾内科,河南省焦作市454000
Author(s):
DU Yanna LI Yanbin WANG Wenjing CUI Baolun
Department of Nephrology, the 988th Hospital of Joint Logistics Support Force of Chinese People′s Liberation Army, Jiaozuo 454000, Henan province, China
关键词:
血液灌流血液透析滤过慢性肾脏病矿物质与骨异常
Keywords:
Hemoperfusion Hemodiafiltration Chronic kidney disease Mineral and bone disorder
分类号:
R 692.5
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2020.06.06
文献标志码:
A
摘要:
目的探讨血液灌流(HP)串联血液透析滤过(HDF)对血液透析慢性肾脏病患者矿物质与骨异常(CKD-MBD)的影响。方法选择2018年10月至2020年2月在我院行维持性血液透析治疗的CKD-MBD患者92例,采用随机数字法分为两组,每组46例。在常规治疗的基础上,对照组患者给予单纯血液透析(HD)治疗,观察组患者在HD治疗的基础上给予HP串联HDF治疗,疗程3个月。比较两组患者治疗前后的血钙、血磷、全段甲状旁腺激素(iPTH)、Ⅰ型前胶原氨基端前肽(PINP)、Ⅰ型胶原羟基端肽β降解产物(β-CTX)、尿酸(UA)、血尿素氮(BUN)、血肌酐(Scr)水平。结果治疗前,两组患者的血钙、血磷及iPTH水平比较,差异无统计学意义(P>0.05);治疗3个月后,观察组患者的血磷及iPTH水平明显低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的PINP、β-CTX水平比较,差异无统计学意义(P>0.05);治疗3个月后,观察组患者的PINP、β-CTX水平均显著低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的UA、BUN及Scr水平比较,差异无统计学意义(P>0.05);治疗3个月后,观察组患者的UA、BUN及Scr水平均显著低于对照组,差异有统计学意义(P<0.05)。结论血液灌流串联血液透析滤过可有效清除维持性血液透析CKD-MBD患者机体内的大中分子毒素,纠正矿物质与骨代谢紊乱状况,有利于改善患者预后。
Abstract:
ObjectiveTo explore the effect of hemoperfusion (HP) and hemodiafiltration (HDF) on chronic kidney disease mineral and bone disorder (CKD-MBD) in hemodialysis patients. MethodsA total of 92 patients with MBD who underwent maintenance hemodialysis in our hospital from October 2018 to February 2020 were selected, and they were divided into two groups by the random number method, with 46 cases in each group. On the basis of conventional treatment, patients in the control group were given simple hemodialysis (HD) for treatment, based on which patients in the observation group were given HP combined with HDF for treatment, with a three-month treatment course. The blood calcium, blood phosphorus, intact parathyroid hormone (iPTH), procollagen type Ⅰ N-terminal propeptide (PINP), C-terminal cross-linking telopeptide of typeⅠcollagen (β-CTX), uric acid (UA), blood urea nitrogen (BUN), blood creatinine (Scr) levels before and after treatment were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in blood calcium, blood phosphorus and iPTH levels between the two groups (P>0.05). After 3 months of treatment, the blood phosphorus and iPTH levels of the observation group were significantly lower than those of the control group, with statistically significant differences (P<0.05). Before treatment, there were no statistically significant differences in the levels of PINP and β-CTX between the two groups (P>0.05). After 3 months of treatment, the levels of PINP and β-CTX in the observation group were significantly lower than those in the control group, with statistically significant differences (P<0.05). Before treatment, there were no statistically significant differences in the levels of UA, BUN and Scr between the two groups (P>0.05). After 3 months of treatment, the levels of UA, BUN and Scr in the observation group were significantly lower than those in the control group, with statistically significant differences (P<0.05). ConclusionHP combined with HDF can effectively remove large and medium molecular toxins in CKD-MBD patients with maintenance hemodialysis, correct mineral and bone metabolism disorders, and help to improve the prognosis of patients.

相似文献/References:

[1]莫小琼,蓝惠珍,莫如珍,等.血液透析滤过治疗尿毒症顽固性高血压的疗效观察与护理[J].内科,2014,(05):588.
[2]罗建宇 王晓源 吕光宇 蒋文芳.血液灌流在急危重患者治疗中的应用进展[J].内科,2015,(03):386.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.43]
 [J].Internal Medicine of China,2015,(06):386.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.43]
[3]黄伟彬 陈卫英 廖新媛.脂肪乳联合血液灌流治疗重度有机磷农药中毒效果分析[J].内科,2015,(05):694.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.05.36]
 [J].Internal Medicine of China,2015,(06):694.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.05.36]
[4]何发标.血液灌流联合连续性肾脏替代治疗中毒致急性肾功能衰竭效果观察[J].内科,2013,(01):35.
 [J].Internal Medicine of China,2013,(06):35.
[5]林芸.血液灌流治疗重度有机磷农药中毒26例观察与护理[J].内科,2012,(02):199.
 [J].Internal Medicine of China,2012,(06):199.
[6]吕海莲,黄玲,吴新莲.血液灌流联合连续性静脉-静脉血液滤过在重症急性胰腺炎中的应用与护理[J].内科,2012,(06):678.
 [J].Internal Medicine of China,2012,(06):678.
[7]王露.血液透析联合血液灌流治疗尿毒症的疗效及安全性分析[J].内科,2015,(06):831.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.06.23]
 [J].Internal Medicine of China,2015,(06):831.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.06.23]
[8]潘习彰,郑娟.血液灌流串联血液透析治疗尿毒症顽固性皮肤瘙痒的临床观察[J].内科,2011,(01):17.
 PAN Xi-Zhang,ZHENG Juan.Clinical comparative analysis of using hemoperfusion and hemodialysis in series in treating refractory uremic pruritus[J].Internal Medicine of China,2011,(06):17.
[9]唐盛,龚智峰*,闭闵,等.血液透析滤过对尿毒症患者心脏功能的影响▲[J].内科,2010,(06):565.
 TANG Sheng,GONG Zhi-feng BI Min,LIU Yun-fang,et al.The impact of hemodiafiltration on cardiac function of patients with uremia[J].Internal Medicine of China,2010,(06):565.
[10]廖丽华.血液灌流治疗急性重症有机磷农药中毒的护理及效果观察[J].内科,2016,(02):310.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.02.54]
 [J].Internal Medicine of China,2016,(06):310.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.02.54]
[11]蒙陆丹,石宏斌,潘松球,等.血液透析滤过联合血液灌流治疗对维持性血透失眠患者睡眠质量及生活质量的影响[J].内科,2012,(04):355.
 [J].Internal Medicine of China,2012,(06):355.

备注/Memo

备注/Memo:
▲基金项目:2016河南省科技攻关计划项目(162102310216)
更新日期/Last Update: 2021-01-11